Exicure Expands Leadership Team with Appointment of TLR9 Oncology Expert Matthias Schroff as Chief Operating Officer

Dr. Schroff is a biotechnology industry veteran who brings more than 15 years of senior leadership experience within global biopharmaceutical companies where he gained deep scientific and clinical experience in immuno-oncology, TLR9 biology and broad clini ...

Overcoming the Challenges of Immuno-Oncology Biomarker Discovery: From Sample to Analytics, New Webinar Hosted by Xtalks

Generating high-quality data when working with limited sample material or degraded or archival specimens Decreasing the risk of missing potential targets with comprehensive assays Going beyond PD-L1 and TMB to complex immuno-oncology biomarkers and ...

Polyphor Ltd: U.S. FDA grants Fast Track designation for Polyphor's innovative immuno-oncology candidate balixafortide in combination with eribulin

U.S. FDA grants Fast Track designation for Polyphor's innovative immuno-oncology candidate balixafortide in combination with eribulin as third line therapy for metastatic breast cancer Polyphor announced today that the U.S. Food and Drug Administration ...

OncoMed Pharma (OMED) Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at AACR

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, presented ...

ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program

LOS ANGELES, April 12, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the Company) (NYSE American: IMUC) announced today that it has been able to verify successful transfer of the selected T cell receptor genetic material into ...